Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

Item

http://www.wikidata.org/entity/Q37125268

Q37125268

about

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Angiotensin receptor blockers for heart failure The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Comparing angiotensin II receptor blockers on benefits beyond blood pressure Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.Zofenopril and incidence of cough: a review of published and unpublished data.Failure or success of electronic search strategies to identify adverse effects data.The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital Comorbid Heart Failure and Renal Impairment: Epidemiology and Management.Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Therapeutic inhibition of the renin angiotensin aldosterone system.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Chronic heart failure: current evidence, challenges to therapy, and future directions.Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?Renin inhibitors and cardiovascular and renal protection: an endless quest?The neurohormonal network in the RAAS can bend before breaking.Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.Targeting the renin-angiotensin-aldosterone system in heart failure.Renin-angiotensin system blocking drugs.Treatment strategies for myocardial recovery in heart failure.Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice.Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors Of fads, fashion, surrogate endpoints and dual RAS blockade.Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF).The performance of adverse effects search filters in MEDLINE and EMBASE.Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus.Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.Neurohumoral effects of aliskiren in patients with symptomatic heart failure receiving a mineralocorticoid receptor antagonist: the Aliskiren Observation of Heart Failure Treatment study.

P2860

Q21092360-FF9F4882-FE6E-4332-BF0C-401EF39FF161 Q24199125-0E3BC16C-ADD6-40FA-AE94-CF00E065479A Q27860581-1961F199-6AFF-4961-8930-F2139894D62D Q28748219-9A32928E-0914-4315-9D38-6C505ED250CB Q30360678-48F68133-C69C-4756-AC86-AEC7543BB1D2 Q30452640-EBFD75F0-A539-460A-8538-0C5F634B4B33 Q33574805-57E02A48-9E72-4D9C-A791-321C08D42EC7 Q33674294-0E98E279-F82A-4576-AAD4-49689057B404 Q33783689-F5AEEC82-5DD6-4A08-AD73-A829CDBF61A6 Q33809879-D564E1E8-ED29-48F5-B02D-3BFC504D8D8D Q34097737-F3978C74-4302-495D-9FDE-CE7D1634A9DA Q34238325-2C496C42-68EB-4698-94F5-545E245B41E7 Q34765075-4546A3F2-C88D-470F-A7AE-E72DEEA0F4DA Q35906518-0ED6C24C-B876-476C-B794-198B525031FD Q36551356-1A8B146F-3019-47BB-B9B3-E1798E617CA2 Q36567554-D4F633B2-564B-4F89-89D9-C2BC143383CF Q37053287-D3E7B660-FF8A-40E4-980E-58A541C84155 Q37489951-F71BA2D5-1103-48D0-A889-A9A903A496C8 Q37574913-4C7EA742-7D93-4F18-A9B4-F373B23BEA58 Q37759964-264F4C41-06B9-43C2-8B98-1D37645D1340 Q37781702-136F37AA-B685-456F-8F2C-7AA013CAB760 Q37880858-581D9224-4458-453E-A9A0-0A8FF3322C59 Q37947405-9402F3F8-6244-4DB0-AEA1-53817B739D37 Q37990796-E9024498-0CAA-4A8A-97BD-31D7E79DF022 Q38005037-4142E813-E378-4534-B8CE-04E6CF91846F Q38010258-9DFA5403-639A-4DDB-ADA1-12DD150AD81B Q38074092-CE76175A-0EA1-4FE1-ACCC-258A41A5E8CE Q38137851-763A7E9A-762F-4B81-B3AB-F71470F33C23 Q38184921-47916402-6687-49F2-A612-B0761944DFE5 Q38275264-20D969EC-EF04-4D33-BCE4-7FF60F6D0E3C Q38416821-D99BD673-A1A2-402E-B45C-5948686404E7 Q39416346-55EA9E06-B088-4057-932C-6C4AE7BE5789 Q42045329-29B78A81-F175-4F89-A248-409A6384A5A9 Q42946303-5C173385-3E48-455A-AFC0-8B967AEF9F0F Q43101047-437420AC-8609-4FBA-A152-A4ACB622A80A Q44546996-22830B4B-50FD-4A5B-B227-98EFCEAB6F3A Q45741432-D7E61BC0-3927-469C-874D-F7CCA1300574 Q49022238-E9579D0A-117E-4778-8435-96C7B070EA30 Q51581858-27E04E0B-31DD-4151-92AB-E13AAE86D942

P2860

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

Item

http://www.wikidata.org/entity/Q37125268

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs